1,720,977 research outputs found
Deep sclerectomy without absorbable implant and with unsutured superficial flap: Prospective randomized clinical trial vs. trabeculectomy with releasable sutures
No full textDeep sclerectomy without absorbable implants and with unsutured scleral flap: prospective, randomised 2-year clinical trial vs trabeculectomy with releasable sutures
No full textEffect of 0.03% bimatoprost on patients non-responders to 0.005% latanoprost: A cross-over study
No full text
Effect of brimonidine on intraocular pressure in normal tension glaucoma: A short term clinical trial
No full textPURPOSE. To evaluate the efficacy and safety of 0.2% brimonidine eye drops given twice daily in normal tension glaucoma. PATIENTS AND METHODS. Sixteen consecutive patients fulfilling eligibility criteria (glaucomatous optic neuropathy associated with visual field defect in at least one eye, intraocular pressure (IOP) less than or equal to 18 mmHg (average of the two highest readings of the round-the-clock curve, including one reading at midnight in supine position), no prior glaucoma therapy, angle wide open, visual acuity 20/40 or better) were enrolled in this prospective, randomized, placebo-controlled clinical trial with crossover design, lasting 30 days for each treatment phase plus 15-day washout in between. Main outcome was IOP (average of the two highest readings of the round-the-clock curve). RESULTS. Mean IOP was significantly reduced by brimonidine (from 17.1 +/- 0.7 mm Hg to 13.9 +/- 2.2 mmHg, p < 0.001 (paired Student t-test)). At the end of the 30-day brimonidine phase, 4 of 16 subjects showed a greater than or equal to 30% IOP decrease over baseline. CONCLUSIONS. In the short term, 0.2% brimonidine eye drops can induce a significant IOP decrease in eyes with normal tension glaucoma
Testing contrast sensitivity upon acute IOP reduction to identify pressure sensitive low-tension glaucomas: a 5-year clinical trial
No full textImprovement of spatial contrast sensitivity threshold after surgical reduction of intraocular pressure in unilateral high-tension glaucoma
No full textIncidence of bronchial hyper reactivity in glaucomatous subjects upon longterm use of topical beta blockers
No full textBeta-Adrenergic Antagonists in the Treatment of Glaucoma
No full textPurpose Beta-blockers have been used since the late 1970's as ‘first-choice’ in the treatment for glaucoma. Since the introduction of new molecules in clinical routine, the current role of beta-blockers in glaucoma therapy has been rediscussed. In particular, concerns have been raised regarding their actual safety profile. Methods This review will focus on the latest advances on the efficacy and safety profiles of non-selective beta-blockers. Conclusions The data provided will help to trace a more appropriate role for beta-blockers in glaucoma therapy. </jats:sec
- …
